Zoetis Inc (NYSE:ZTS)
| 165.13 Delayed Data As of Jan 27 |  -3.11 / -1.85%Today’s Change | 124.15 Today|||52-Week Range 205.31 | +12.68% Year-to-Date |
Latest ZTS News | Press Releases
| 4 Top Stocks With High Dividend Growth to Buy in 2023 and Hold Forever 10:15am / MotleyFool.com - Paid Partner Content | If You Invested $5,000 in Zoetis in 2013, This Is How Much You Would Have Today Jan 18 / MotleyFool.com - Paid Partner Content |
| Zoetis (ZTS) Stock Sinks As Market Gains: What You Should Know Jan 27 / Zacks.com - Paid Partner Content | 3 Reasons to Buy Zoetis, and 1 Reason to Sell Jan 17 / MotleyFool.com - Paid Partner Content |
| UTHR vs. ZTS: Which Stock Is the Better Value Option? Jan 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 168.24 |
| Today’s open | 167.47 |
| Day’s range | 164.48 - 167.54 |
| Volume | 1,831,718 |
| Average volume (3 months) | 2,286,642 |
| Market cap | $76.3B |
Data as of 4:00pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | +24.66% |
| Earnings growth (this year) | +4.03% |
| Earnings growth (next 5 years) | +10.07% |
| Revenue growth (last year) | +16.49% |
| P/E ratio | 37.7 |
| Price/Sales | 14.96 |
| Price/Book | 17.04 |
Competitors
| ---- | ||
| REGNRegeneron Pharmaceut... | 0.00 | 0.00% |
| GLAXFGlaxoSmithKline | +0.47 | +2.72% |
| GSKGlaxoSmithKline | +0.01 | +0.03% |
Data as of 4:00pm ET, 01/27/2023
Financials
| Next reporting date | February 14, 2023 |
| EPS forecast (this quarter) | $1.15 |
| Annual revenue (last year) | $7.8B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 26.20% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Parsippany, New Jersey |
Forecasts
